ClinicalTrials.gg
CompletedNCT04523571Updated Sep 18, 2023Results posted

Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects

A Phase 1 interventional study of BNT162b1 and Placebo in SARS-CoV-2, sponsored by BioNTech SE. Completed at 1 site in China. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-18.

Sponsored by BioNTech SE · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.

Enrollment
42nd of 54
144 · median 575
Started
2020
with 4 others
Phase 1
Only one
of the 54
Registered
3rd of 54
by date
Lead sponsor
20 of 54
BioNTech SE

Among the 54 studies testing BNT162 Vaccine in COVID-19, this one is the 42nd largest by enrollment, is one of 5 that started in 2020, is the only one in phase 1, and was the 3rd registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About BNT162 Vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing BNT162 Vaccine in COVID-19, or all of them as a file.
02

Study summary

This was a phase I, randomized, placebo-controlled, observer-blind study, for evaluation of safety and immunogenicity of SARS-CoV-2 mRNA vaccine (BNT162b1) in Chinese healthy population.

Read the detailed description

The participants were screened for 2 weeks (Day -14 to Day 0) before randomization, and received 1 dose of SARS-CoV-2 vaccine (BNT162b1) or placebo intramuscularly (IM) on Day 1 and Day 22, respectively. After randomization, the study for each participant lasted for approximately 12 months.

03

Conditions studied

  • SARS-CoV-2

Keywords

  • Protection against COVID-19
  • Coronavirus Disease 2019
  • Coronavirus infection
  • Vaccine
  • RNA Vaccine
  • Virus Diseases
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For adult group (age ≥18 and ≤55)

  • Male or female subjects of ≥18 years old and ≤55 years old with (BMI) ≥18 and ≤30 at the Screening Visit.
  • Individuals who are in good health condition at the time of entry into the trial as determined by medical history, physical examination (including vital signs, [ECG]) and eligibility screening test (hematology, blood chemistry and urine analysis) and clinical judgment of the investigator at Screening Visit.
  • The subject can provide with and signs and dates a written informed consent form (ICF) prior to the initiation of any trial procedures.
  • They must be able to understand and follow trial-related instructions.
  • They must be willing and able to comply with planned visits, treatment schedule, laboratory tests and other requirements of the trial.
  • Negative in antibodies screening of SARS-CoV-2 (fingerstick).
  • Normal in chest computed tomography (CT) scans (no imaging features of COVID-19).
  • Axillary temperature ≤ 37.0ºC.
  • Negative SARS-CoV-2 test in throat swabs by reverse transcription-polymerase chain reaction (RT-PCR).
  • Women of (WOCBP) must have a negative beta-human chorionic gonadotropin (β-hCG) in serum sample at Screening Visit. Women that are (Menopause≥12 consecutive months) or permanently sterilized will be considered as not having .
  • WOCBP must have used effective 14 days prior to screening and agree to use effective contraception continuously during the trial period, from 14 days prior to Screening Visit to 60 days after the last immunization.
  • WOCBP must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during trial, starting from Screening Visit and continuously until 60 days after being given the last immunization.
  • Men who are sexually active with a WOCBP and have not had a vasectomy must agree to practice an effective form of contraception with their female partner of childbearing potential during the trial, starting from Screening Visit and continuously until 60 days after being given the last immunization.
  • Men must be willing to refrain from sperm donation, starting from Screening Visit and continuously until 60 days after receiving the last immunization.

For the elderly group (age ≥65 and ≤85)

  • Male or female subjects ≥65 years old and ≤85 years old at Screening Visit
  • Individuals who are in a health condition that can receive the vaccine, at the time of entry into the trial as determined by medical history, physical examination (including vital signs, ECG) and eligibility screening tests (hematology, biochemistry and urinalysis) and clinical judgment of the investigator at Screening Visit.
  • The subject can provide with informed consent and signs and dates a written ICF prior to the initiation of any trial procedures.
  • They must be able to understand and follow trial-related instructions.
  • They must be willing and able to comply with planned visits, treatment schedule, laboratory tests and other requirements of the trial.
  • Negative in antibodies screening of SARS-CoV-2 (blood sample from fingertip).
  • No imaging features of COVID-19 in chest CT.
  • Axillary temperature ≤ 37.0ºC.
  • Negative SARS-CoV-2 test in throat swabs by RT-PCR.
  • WOCBP must have a negative serum β-hCG at Screening Visit. Women that are postmenopausal (Menopause ≥12 consecutive months) or permanently sterilized will be considered as not having reproductive potential.
  • WOCBP must have used effective contraception 14 days prior to screening and agree to use effective contraception continuously during the trial period, from 14 days prior to Screening Visit to 60 days after the last immunization.
  • WOCBP must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during trial, starting from Screening Visit and continuously until 60 days after being given the last immunization.
  • Men who are sexually active with a WOCBP and have not had a vasectomy must agree to practice an effective form of contraception with their female partner of childbearing potential during the trial, starting from Screening Visit and continuously until 60 days after being given the last immunization.
  • Men must be willing to refrain from sperm donation, starting from Screening Visit and continuously until 60 days after receiving the last immunization.

Exclusion criteria

Exclusion Criteria:

For adult group (age ≥18 and ≤55)

  • Have had any acute illness, as determined by the investigator, with or without fever, within 72 hours prior to the prime vaccination. An acute illness which is nearly resolved with only minor residual symptoms remaining is allowable if, in the opinion of the investigator, the residual symptoms will not compromise their well-being if they participate as trial subjects in the trial, or that could prevent, limit, or confound the protocol-specified assessments.
  • Are breastfeeding on the day of Screening Visit or who plan to breastfeed during the trial, starting from Screening Visit and continuously until at least 90 days after the last immunization. Women or partners who plan to become pregnant within 1 year post the Screening Visit.
  • Have a known allergy, , or intolerance to the planned vaccine for trial including any .
  • Used to have a history of hypersensitivity or serious reactions to vaccination.
  • Received any vaccination within 4 weeks prior to Visit 1.
  • Don't agree to not be vaccinated during the trial, starting from Screening Visit and continuously until 28 days after receiving the last immunization, except emergency vaccination (e.g. rabies vaccine, tetanus vaccine).
  • Had any medical condition (e.g., disease) or any major surgery (e.g., requiring general anesthesia) within the past 5 years, which in the opinion of the investigator, could compromise their well-being if they participate as trial subjects in the trial, or that could prevent, limit, or confound the protocol-specified assessments.
  • Have any surgery planned during the trial, starting from Screening Visit and continuously until at least 90 days after the last immunization.
  • Had any chronic use (more than 14 continuous days) of any systemic medications that affects immune function, including or other immune-modifying drugs, within 6 months prior to Screening Visit unless in the opinion of the investigator, the medication would not prevent, limit, or confound the protocol-specified assessments or could compromise safety of subjects.
  • Had administration of any immunoglobulins and/or any blood products within the 3 months prior to Screening Visit.
  • Had administration of another product including vaccines within 60 days or 5 half-lives (whichever is longer), prior to Screening Visit.
  • With known history of AIDS or (HIV) test positive.
  • History of virus (HBV) or virus (HCV) infection, through medical inquiry.
  • History of SARS, SARS-CoV-2 or middle east respiratory syndrome (MERS) infection. Suspected SARS patients should be screened for SARS antibodies.
  • Previously participated in a clinical trial involving lipid nanoparticles.
  • Are subject to exclusion periods of other clinical trials or simultaneous participation in another clinical trial.
  • Have any affiliation with the study site (e.g., are close relative of the investigator or dependent person, such as an employee or student of the study site).
  • Have a history of drug abuse or known medical, psychological, or social conditions within the past 5 years. In the opinion of the investigator, could comprise their well-being if they participate as trial subjects in the trial, or that could prevent, limit, or confound the protocol-specified assessments.
  • Have a history of narcolepsy.
  • Have history of alcohol abuse or drug addiction within 1 year prior to Screening Visit.
  • Have a history of or suspected immunosuppressive condition, acquired or congenital, as determined by medical history and/or physical examination at Screening Visit.
  • Have any abnormality or permanent body art (e.g., tattoo), that in the opinion of the investigator, would obstruct the ability to observe local reactions at the vaccination site.
  • Have had any blood loss >400 mL, e.g., due to donation of blood or blood products or injury, within the 28 days prior to Screening Visit or plan to donate blood or plasma during the trial, starting from Screening Visit and continuously until at least 28 days after being given the last immunization.
  • Travel or live in any country or region with a high SARS-CoV-2 infection risk (as defined at Screening Visit) within the 14 days prior to Screening Visit.
  • They plan to visit any country or region with a high SARS-CoV-2 infection risk (as defined at Screening Visit), from Screening Visit until 14 days after being given the last immunization.
  • Symptoms of COVID-19, e.g., respiratory symptoms, fever, cough, shortness of breath and breathing difficulties.
  • Have had contact with confirmed COVID-19 patients or persons tested positive for SARS-CoV-2 within the 30 days prior to Screening Visit.
  • Are vulnerable persons, e.g., soldiers, subjects in detention, contract research organization (CRO) or Fosun staff or their family members.

For the elderly group (age ≥65 and ≤85)

  • Baseline laboratory abnormalities with Grade ≥3 (for hematology abnormalities with Grade ≥2) during screening visits, by physical examination and eligibility screening.
  • Have had any acute illness, as determined by the investigator, with or without fever, within 72 hours prior to the prime vaccination. An acute illness which is nearly resolved with only minor residual symptoms remaining is allowable if, in the opinion of the investigator, the residual symptoms will not compromise their well-being if they participate as trial subjects in the trial, or that will not prevent, limit, or confound the protocol-specified assessments.
  • Have a known allergy, hypersensitivity, or intolerance to the planned vaccine for trial including any excipients.
  • Used to have a history of hypersensitivity or serious reactions to vaccination.
  • Received any vaccination within 4 weeks prior to Visit 1.
  • Don't agree to not be vaccinated during the trial, starting from Screening Visit and continuously until 28 days after receiving the last immunization, except emergency vaccination (e.g. rabies vaccine, tetanus vaccine).
  • Had administration of any immunoglobulins and/or any blood products within the 3 months prior to Screening Visit.
  • Had any serious or life-threatening medical condition (e.g., autoimmune disease, cardiovascular disease) within the past 5 years, which in the opinion of the investigator, could compromise their well-being if they participate as trial subjects in the trial, or that could prevent, limit, or confound the protocol-specified assessments.
  • Have any surgery planned during the trial, starting from Screening Visit and continuously until at least 90 days after the last immunization.
  • Had any chronic use (more than 14 continuous days) of any systemic medications that affects immune function, including immunosuppressant or other immune-modifying drugs, within 6 months prior to Screening Visit unless in the opinion of the investigator, the medication would not prevent, limit, or confound the protocol-specified assessments or could compromise safety of subjects.
  • Had administration of another investigational product including vaccines within 60 days or 5 half-lives (whichever is longer), prior to Screening Visit.
  • With known history of AIDS or HIV test positive.
  • History of HBV or HCV infection.
  • History of SARS, SARS-CoV-2 or MERS infection. Suspected SARS patients should be screened for SARS antibodies.
  • Previously participated in a clinical trial involving lipid nanoparticles.
  • Are subject to exclusion periods of other clinical trials or simultaneous participation in another clinical trial.
  • Have any affiliation with the study site (e.g., are close relative of the investigator or dependent person, such as an employee or student of the study site).
  • Have a history of drug abuse or known medical, psychological, or social conditions within the past 5 years. In the opinion of the investigator, could comprise their well-being if they participate as trial subjects in the trial, or that could prevent, limit, or confound the protocol-specified assessments.
  • Have a history of narcolepsy.
  • Have history of alcohol abuse or drug addiction within 1 year prior to Screening Visit.
  • Have a history of or suspected immunosuppressive condition, acquired or congenital, as determined by medical history and/or physical examination at Screening Visit.
  • Have any abnormality or permanent body art (e.g., tattoo), that in the opinion of the investigator, would obstruct the ability to observe local reactions at the vaccination site.
  • Have had any blood loss >400 mL, e.g., due to donation of blood or blood products or injury, within the 28 days prior to Screening Visit or plan to donate blood or plasma during the trial, starting from Screening Visit and continuously until at least 28 days after being given the last immunization.
  • Travel or live in any country or region with a high SARS-CoV-2 infection risk (as defined at Screening Visit) within the 14 days prior to Screening Visit.
  • They plan to visit any country or region with a high SARS-CoV-2 infection risk (as defined at Screening Visit), from Screening Visit until 14 days after being given the last immunization.
  • Symptoms of COVID-19, e.g., respiratory symptoms, fever, cough, shortness of breath and breathing difficulties.
  • Have had contact with confirmed COVID-19 patients or persons tested positive for SARS-CoV-2 nucleic acids or antibodies within the 30 days prior to Screening Visit.
  • Are vulnerable persons, e.g., soldiers, subjects in detention, CRO or Fosun staff or their family members.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    Low-dose, 18-55 years of age

    Biological: BNT162b1

  • Experimental
    High-dose, 18-55 years of age

    Biological: BNT162b1

  • Placebo comparator
    Placebo, 18-55 years of age

    Other: Placebo

  • Experimental
    Low-dose, 65-85 years of age

    Biological: BNT162b1

  • Experimental
    High-dose, 65-85 years of age

    Biological: BNT162b1

  • Placebo comparator
    Placebo, 65-85 years of age

    Other: Placebo

Interventions

  • BiologicalBNT162b1

    Intramuscular injection

  • OtherPlacebo

    Intramuscular injection

06

What researchers measure

Primary outcomes

  1. Number of Participants With Solicited Local Adverse Events (AEs) (e.g., Injection Site Pain, Redness, Induration, Swelling) Recorded up to 14 Days After Each Dose of BNT162b1 or Placebo.

    Solicited local AEs were collected within 7 days/14 days after each vaccination. For the grading of AEs, a 7-day period AE assessment after each dose as graded by United States (US) Food and Drug Administration (FDA) criteria along with the 14-day period AE assessment as graded by National Medical Products Administration (NMPA) criteria are used to evaluate solicited AEs. For other AEs, only the NMPA criteria is used. The "solicited" AEs were pre-defined and listed in the subjects' diaries. All the solicited local AEs occurred within 7 days after vaccination were related to investigational vaccine (or placebo).

    Time frame: Up to 14 days following each dose administration

  2. Number of Participants With Solicited Systemic AEs (e.g., e.g., Nausea, Vomiting, Diarrhea, Headache, Fatigue, Myalgia, Arthralgia, Chills, Loss of Appetite, Malaise, and Fever) Recorded up to 14 Days After Each Dose of BNT162b1 or Placebo.

    Solicited systemic AEs were collected within 7 days/14 days after each vaccination. For the grading of AEs, a 7-day period AE assessment after each dose as graded by US FDA criteria along with the 14-day period AE assessment as graded by NMPA criteria are used to evaluate solicited AEs. For other AEs, only the NMPA criteria is used. The "solicited" AEs were pre-defined and listed in the subjects' diaries. Except for 1 event (myalgia) occurred in 10 µg group and 1 event (diarrhea) occurred in placebo group, all the solicited systemic AEs occurred within 7 days after vaccination were related to investigational vaccine (or placebo). All the solicited systemic AEs occurred within 14 days after vaccination were related to investigational vaccine (or placebo), except for 1 event (myalgia) occurred in placebo group and 2 events (both diarrhea; 1 event occurred in 30 µg group, 1 event occurred in placebo group).

    Time frame: Up to 14 days following each dose administration

  3. Number of Participants With Unsolicited Vaccine Related AEs During the 21-day Period After Dose 1 of BNT162b1 or Placebo.

    AEs occurred during the 21-day period after dose 1 were also referred as "unsolicited" AEs. The unsolicited AEs were not pre-defined in the subjects' diaries.

    Time frame: 21-day period after dose 1 vaccination

  4. Number of Participants With Unsolicited Vaccine Related AEs During the 28-day Period After Dose 2 of BNT162b1 or Placebo.

    AEs occurred during the 28-day period after dose 2 were also referred as "unsolicited" AEs. The unsolicited AEs were not pre-defined in the subjects' diaries.

    Time frame: 28-day period after dose 2 vaccination

Secondary outcomes

  1. The Number of Participants Experiencing Treatment Emergent Serious Adverse Events (TESAEs)

    Time frame: From Dose 1 up to Month 12

  2. The Number of Participants Experiencing Related TEAEs

    "Related" implies the relationship between AE and vaccine is one of "Possibly related", "Probably related" and "Definitely related".

    Time frame: From Dose 1 up to Month 12

  3. The Number of Participants Experiencing Clinically Significant (CS) Abnormal Markers of Hematology, Blood Chemistry and Urine Analysis

    Results for CS results are displayed by abnormal parameter. Abnormal test results assessed not clinical significant are not presented. Participants with more than one 'CS' parameter are counted for each parameter separately and therefore included multiple times.

    Time frame: Hour 24 and Day 7 after dose 1 and Day 7 after dose 2

  4. Geometric Mean Titer (GMT) of Anti-S1 IgG Antibody

    At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6 and 12 after dose 1.

    Time frame: Up to 12 months following first dose

  5. GMT of Anti-receptor Binding Domain (RBD) Immunoglobulin G (IgG) Antibody

    At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6 and 12 after dose 1.

    Time frame: Up to 12 months following first dose

  6. GMT of SARS-CoV-2 Neutralizing Antibody (Including True Virus-based SARS-CoV-2 Neutralizing Test)

    At Day 7, Day 21 after first dose, at Day 7, Day 21 after second dose, and at Month 3, 6, and 12 after first dose.

    Time frame: Up to 12 months following first dose

  7. Fold Increase in Antibody Anti-S1 IgG Antibody Titers, as Compared to Baseline

    At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6, and 12 after dose 1.

    Time frame: Up to 12 months following the first dose

  8. Fold Increase in Antibody Anti-RBD IgG Antibody Titers, as Compared to Baseline

    At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6, and 12 after dose 1.

    Time frame: Up to 12 months following first dose

  9. Fold Increase in SARS-CoV-2 Neutralizing Antibody Titers (Virus Neutralizing Test), as Compared to Baseline.

    At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6, and 12 after dose 1.

    Time frame: Up to 12 months following first dose

  10. Seroconversion Rates (SCR) Defined as a Minimum of 4-fold Increase of Antibody Titers, as Compared to Baseline

    At Day 7, Day 21 after dose 1, and at Day 7, Day 21 after dose 2.

    Time frame: Up to 21 days after dose 2

07

Results

Posted Sep 18, 2023

Participant flow

A total of 144 subjects were randomized in this phase I clinical trial, including 72 adult subjects aged 18-55 years old (including boundary value) and 72 elderly subjects aged 65-85 years old (including boundary value). The subjects received either BNT162b1 10 µg (low dose), BNT162b1 30 µg (high dose), or placebo on Day 1 and Day 22, respectively.

Received 2 Doses
Participant flow — Received 2 Doses
MilestoneLow-dose 10 µg, 18-55 Years of AgeHigh-dose 30 µg, 18-55 Years of AgePlacebo, 18-55 Years of AgeLow-dose 10 µg, 65-85 Years of AgeHigh-dose 30 µg, 65-85 Years of AgePlacebo, 65-85 Years of Age
Started242424242424
Completed242424232324
Not completed000110
Withdrew: Withdrawal by subject000110
Received 2 Doses and Completed Follow-up
Participant flow — Received 2 Doses and Completed Follow-up
MilestoneLow-dose 10 µg, 18-55 Years of AgeHigh-dose 30 µg, 18-55 Years of AgePlacebo, 18-55 Years of AgeLow-dose 10 µg, 65-85 Years of AgeHigh-dose 30 µg, 65-85 Years of AgePlacebo, 65-85 Years of Age
Started242424232324
Completed232423222223
Not completed101111
Withdrew: Inoculated with other covid-19 vaccine101000
Withdrew: Withdrawal by subject000001
Withdrew: Adverse event000110

Outcome measures

PrimaryNumber of Participants With Solicited Local Adverse Events (AEs) (e.g., Injection Site Pain, Redness, Induration, Swelling) Recorded up to 14 Days After Each Dose of BNT162b1 or Placebo.

Solicited local AEs were collected within 7 days/14 days after each vaccination. For the grading of AEs, a 7-day period AE assessment after each dose as graded by United States (US) Food and Drug Administration (FDA) criteria along with the 14-day period AE assessment as graded by National Medical Products Administration (NMPA) criteria are used to evaluate solicited AEs. For other AEs, only the NMPA criteria is used. The "solicited" AEs were pre-defined and listed in the subjects' diaries. All the solicited local AEs occurred within 7 days after vaccination were related to investigational vaccine (or placebo).

Time frame:
Up to 14 days following each dose administration
Reported as:
Count of participants · Participants
Number of Participants With Solicited Local Adverse Events (AEs) (e.g., Injection Site Pain, Redness, Induration, Swelling) Recorded up to 14 Days After Each Dose of BNT162b1 or Placebo.
ParticipantsLow-dose 10 µg, 18-55 Years of AgeHigh-dose 30 µg, 18-55 Years of AgePlacebo, 18-55 Years of AgeLow-dose 10 µg, 65-85 Years of AgeHigh-dose 30 µg, 65-85 Years of AgePlacebo, 65-85 Years of Age
Within 7 days after dose 1: Number of participants with solicited local AEs1924113190
Within 7 days after dose 2: Number of participants with solicited local AEs1720115150
Within 7 days after dose 1: Number of participants with solicited local AEs grade 3 (FDA criteria)000000
Within 7 days after dose 2: Number of participants with solicited local AEs grade 3 (FDA criteria)000000
Within 14 days after dose 1: Number of participants with solicited local AEs grade 3 (NMPA criteria)000000
Within 14 days after dose 2: Number of participants with solicited local AEs grade 3 (NMPA criteria)000000
PrimaryNumber of Participants With Solicited Systemic AEs (e.g., e.g., Nausea, Vomiting, Diarrhea, Headache, Fatigue, Myalgia, Arthralgia, Chills, Loss of Appetite, Malaise, and Fever) Recorded up to 14 Days After Each Dose of BNT162b1 or Placebo.

Solicited systemic AEs were collected within 7 days/14 days after each vaccination. For the grading of AEs, a 7-day period AE assessment after each dose as graded by US FDA criteria along with the 14-day period AE assessment as graded by NMPA criteria are used to evaluate solicited AEs. For other AEs, only the NMPA criteria is used. The "solicited" AEs were pre-defined and listed in the subjects' diaries. Except for 1 event (myalgia) occurred in 10 µg group and 1 event (diarrhea) occurred in placebo group, all the solicited systemic AEs occurred within 7 days after vaccination were related to investigational vaccine (or placebo). All the solicited systemic AEs occurred within 14 days after vaccination were related to investigational vaccine (or placebo), except for 1 event (myalgia) occurred in placebo group and 2 events (both diarrhea; 1 event occurred in 30 µg group, 1 event occurred in placebo group).

Time frame:
Up to 14 days following each dose administration
Reported as:
Count of participants · Participants
Number of Participants With Solicited Systemic AEs (e.g., e.g., Nausea, Vomiting, Diarrhea, Headache, Fatigue, Myalgia, Arthralgia, Chills, Loss of Appetite, Malaise, and Fever) Recorded up to 14 Days After Each Dose of BNT162b1 or Placebo.
ParticipantsLow-dose 10 µg, 18-55 Years of AgeHigh-dose 30 µg, 18-55 Years of AgePlacebo, 18-55 Years of AgeLow-dose 10 µg, 65-85 Years of AgeHigh-dose 30 µg, 65-85 Years of AgePlacebo, 65-85 Years of Age
Within 7 d (days) after dose 1: Number of participants with solicited systemic AEs91633152
Within 7 d after dose 2: Number of participants with solicited systemic AEs152137171
Within 14 d after dose 1: Number of participants with solicited systemic AEs101633152
Within 14 d after dose 2: Number of participants with solicited systemic AEs152137172
Within 7 d after dose 1: Number of participants with related solicited systemic AEs grade 3 (FDA)010020
Within 7 d after dose 2: Number of participants with related solicited systemic AEs grade 3 (FDA)130000
Within 14 d after dose 1: Number of participants with related solicited systemic AEs grade 3 (NMPA)050020
Within 14 d after dose 2: Number of participants with related solicited systemic AEs grade 3 (NMPA)360000
PrimaryNumber of Participants With Unsolicited Vaccine Related AEs During the 21-day Period After Dose 1 of BNT162b1 or Placebo.

AEs occurred during the 21-day period after dose 1 were also referred as "unsolicited" AEs. The unsolicited AEs were not pre-defined in the subjects' diaries.

Time frame:
21-day period after dose 1 vaccination
Reported as:
Number · participants
Number of Participants With Unsolicited Vaccine Related AEs During the 21-day Period After Dose 1 of BNT162b1 or Placebo.
participantsLow-dose 10 µg, 18-55 Years of AgeHigh-dose 30 µg, 18-55 Years of AgePlacebo, 18-55 Years of AgeLow-dose 10 µg, 65-85 Years of AgeHigh-dose 30 µg, 65-85 Years of AgePlacebo, 65-85 Years of Age
Number of Participants With Unsolicited Vaccine Related AEs During the 21-day Period After Dose 1 of BNT162b1 or Placebo.771252
PrimaryNumber of Participants With Unsolicited Vaccine Related AEs During the 28-day Period After Dose 2 of BNT162b1 or Placebo.

AEs occurred during the 28-day period after dose 2 were also referred as "unsolicited" AEs. The unsolicited AEs were not pre-defined in the subjects' diaries.

Time frame:
28-day period after dose 2 vaccination
Reported as:
Number · participants
Number of Participants With Unsolicited Vaccine Related AEs During the 28-day Period After Dose 2 of BNT162b1 or Placebo.
participantsLow-dose 10 µg, 18-55 Years of AgeHigh-dose 30 µg, 18-55 Years of AgePlacebo, 18-55 Years of AgeLow-dose 10 µg, 65-85 Years of AgeHigh-dose 30 µg, 65-85 Years of AgePlacebo, 65-85 Years of Age
Number of Participants With Unsolicited Vaccine Related AEs During the 28-day Period After Dose 2 of BNT162b1 or Placebo.580270
SecondaryThe Number of Participants Experiencing Treatment Emergent Serious Adverse Events (TESAEs)
Time frame:
From Dose 1 up to Month 12
Reported as:
Number · participants
The Number of Participants Experiencing Treatment Emergent Serious Adverse Events (TESAEs)
participantsLow-dose 10 µg, 18-55 Years of AgeHigh-dose 30 µg, 18-55 Years of AgePlacebo, 18-55 Years of AgeLow-dose 10 µg, 65-85 Years of AgeHigh-dose 30 µg, 65-85 Years of AgePlacebo, 65-85 Years of Age
The Number of Participants Experiencing Treatment Emergent Serious Adverse Events (TESAEs)011100
SecondaryThe Number of Participants Experiencing Related TEAEs

"Related" implies the relationship between AE and vaccine is one of "Possibly related", "Probably related" and "Definitely related".

Time frame:
From Dose 1 up to Month 12
Reported as:
Number · participants
The Number of Participants Experiencing Related TEAEs
participantsLow-dose 10 µg, 18-55 Years of AgeHigh-dose 30 µg, 18-55 Years of AgePlacebo, 18-55 Years of AgeLow-dose 10 µg, 65-85 Years of AgeHigh-dose 30 µg, 65-85 Years of AgePlacebo, 65-85 Years of Age
Number of Participants with related TEAEs after dose 12224416214
Number of Participants with related TEAEs after dose 22022418210
SecondaryThe Number of Participants Experiencing Clinically Significant (CS) Abnormal Markers of Hematology, Blood Chemistry and Urine Analysis

Results for CS results are displayed by abnormal parameter. Abnormal test results assessed not clinical significant are not presented. Participants with more than one 'CS' parameter are counted for each parameter separately and therefore included multiple times.

Time frame:
Hour 24 and Day 7 after dose 1 and Day 7 after dose 2
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Clinically Significant (CS) Abnormal Markers of Hematology, Blood Chemistry and Urine Analysis
ParticipantsLow-dose 10 µg, 18-55 Years of AgeHigh-dose 30 µg, 18-55 Years of AgePlacebo, 18-55 Years of AgeLow-dose 10 µg, 65-85 Years of AgeHigh-dose 30 µg, 65-85 Years of AgePlacebo, 65-85 Years of Age
CS abnormal blood chemistry parameter - increased total bilirubin - 24 hours after dose 1010000
CS abnormal blood chemistry parameter - increased total bilirubin - Day 7 after dose 1000000
CS abnormal blood chemistry parameter - increased total bilirubin - Day 7 after dose 2000000
CS abnormal urine routine test results - elevated leucocyte (microscopic) - 24 hours after dose 1101001
CS abnormal urine routine test results - elevated leucocyte (microscopic) - Day 7 after dose 1000100
CS abnormal urine routine test results - elevated leucocyte (microscopic) - Day 7 after dose 2000000
CS abnormal urine routine test results - bacteria (microscopic) - 24 hours after dose 1101001
CS abnormal urine routine test results - bacteria (microscopic) - Day 7 after dose 1000101
CS abnormal urine routine test results - bacteria (microscopic) - Day 7 after dose 2000100
CS abnormal urine routine test results - red blood cells (microscopic) - 24 hours after dose 1000000
CS abnormal urine routine test results - red blood cells (microscopic) - Day 7 after dose 1000000
CS abnormal urine routine test results - red blood cells (microscopic) - Day 7 after dose 2000100
CS abnormal urine routine test results - glucose - 24 hours after dose 1000000
CS abnormal urine routine test results - glucose - Day 7 after dose 1000010
CS abnormal urine routine test results - glucose - Day 7 after dose 2000000
CS abnormal urine routine test results - ketone - 24 hours after dose 1000000
CS abnormal urine routine test results - ketone - Day 7 after dose 1000010
CS abnormal urine routine test results - ketone - Day 7 after dose 2000000
CS abnormal urine routine test results - blood - 24 hours after dose 1000000
CS abnormal urine routine test results - blood - Day 7 after dose 1000000
CS abnormal urine routine test results - blood - Day 7 after dose 2000100
CS abnormal hematology parameter - hemoglobin - 24 hours after dose 1000000
CS abnormal hematology parameter - hemoglobin - Day 7 after dose 1100000
CS abnormal hematology parameter - hemoglobin - Day 7 after dose 2110000
CS abnormal hematology parameter - hematocrit - 24 hours after dose 1000000
CS abnormal hematology parameter - hematocrit - Day 7 after dose 1100000
CS abnormal hematology parameter - hematocrit - Day 7 after dose 2110000
CS abnormal hematology parameter - lymphocyte - 24 hours after dose 1350000
CS abnormal hematology parameter - lymphocyte - Day 7 after dose 1000001
CS abnormal hematology parameter - lymphocyte - Day 7 after dose 2000000
CS abnormal hematology parameter - platelet count - 24 hours after dose 1020120
CS abnormal hematology parameter - platelet count - Day 7 after dose 1001100
CS abnormal hematology parameter - platelet count - Day 7 after dose 2002100
SecondaryGeometric Mean Titer (GMT) of Anti-S1 IgG Antibody

At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6 and 12 after dose 1.

Time frame:
Up to 12 months following first dose
Reported as:
Geometric mean · titer
Geometric Mean Titer (GMT) of Anti-S1 IgG Antibody
titerLow-dose 10 µg, 18-55 Years of AgeHigh-dose 30 µg, 18-55 Years of AgePlacebo, 18-55 Years of AgeLow-dose 10 µg, 65-85 Years of AgeHigh-dose 30 µg, 65-85 Years of AgePlacebo, 65-85 Years of Age
7 days after dose 153.320 (46.680 to 60.905)59.220 (41.728 to 84.046)52.841 (47.132 to 59.242)———
21 days after dose 14193.710 (2664.050 to 6601.681)4531.416 (3029.130 to 6778.757)52.594 (47.369 to 58.395)859.646 (467.549 to 1580.564)2872.861 (1685.729 to 4896.002)62.239 (47.583 to 81.410)
7 days after dose 226548.853 (18381.541 to 38345.078)41530.498 (33984.171 to 50752.518)52.578 (47.384 to 58.341)5271.560 (2484.575 to 11184.748)23447.197 (15268.301 to 36007.348)62.658 (47.633 to 82.423)
21 days after dose 246810.469 (41673.251 to 52580.970)49773.381 (46947.113 to 52769.794)50.000 (50.000 to 50.000)40942.862 (33177.420 to 50525.869)44159.581 (37139.275 to 52506.910)61.008 (45.725 to 81.399)
Month 3 after dose 127143.015 (21023.440 to 35043.897)31584.450 (26378.938 to 37817.196)50.000 (50.000 to 50.000)———
Month 6 after dose 14169.448 (2978.898 to 5835.815)5693.082 (4412.125 to 7345.934)55.088 (47.853 to 63.417)2223.699 (1565.907 to 3157.811)4970.376 (3625.506 to 6814.121)60.931 (45.837 to 80.995)
Month 12 after dose 12002.152 (1389.905 to 2884.090)2792.605 (2118.269 to 3681.610)50.000 (50.000 to 50.000)1104.860 (698.932 to 1746.542)2847.010 (1887.353 to 4294.621)53.105 (46.867 to 60.174)
SecondaryGMT of Anti-receptor Binding Domain (RBD) Immunoglobulin G (IgG) Antibody

At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6 and 12 after dose 1.

Time frame:
Up to 12 months following first dose
Reported as:
Geometric mean · titer
GMT of Anti-receptor Binding Domain (RBD) Immunoglobulin G (IgG) Antibody
titerLow-dose 10 µg, 18-55 Years of AgeHigh-dose 30 µg, 18-55 Years of AgePlacebo, 18-55 Years of AgeLow-dose 10 µg, 65-85 Years of AgeHigh-dose 30 µg, 65-85 Years of AgePlacebo, 65-85 Years of Age
7 days after dose 150.000 (50.000 to 50.000)52.903 (47.074 to 59.453)56.644 (48.999 to 65.482)———
21 days after dose 113095.167 (8395.009 to 20426.827)13046.378 (8950.882 to 19015.777)56.699 (49.052 to 65.537)3040.808 (1569.768 to 5890.369)10370.854 (5955.358 to 18060.142)74.476 (55.679 to 99.618)
7 days after dose 238314.550 (30173.509 to 48652.107)47324.691 (43213.653 to 51826.824)57.377 (49.028 to 67.146)10748.566 (5512.317 to 20958.821)38256.083 (30078.753 to 48656.534)75.817 (55.962 to 102.715)
21 days after dose 249710.291 (46764.743 to 52841.369)51200.000 (51200.000 to 51200.000)60.605 (48.454 to 75.804)46980.825 (42021.855 to 52525.000)50977.162 (50528.938 to 51429.363)65.756 (53.237 to 81.218)
Month 3 after dose 140236.195 (32999.573 to 49059.768)43050.715 (38767.819 to 47806.766)60.439 (49.911 to 73.188)———
Month 6 after dose 18249.604 (6186.091 to 11001.449)9608.488 (7410.049 to 12459.167)61.768 (50.272 to 75.894)4114.353 (2716.614 to 6231.250)7187.827 (5138.636 to 10054.194)54.780 (48.060 to 62.439)
Month 12 after dose 12324.072 (1677.862 to 3219.163)2804.882 (2191.409 to 3590.094)56.083 (47.501 to 66.216)1536.143 (921.738 to 2560.094)2768.366 (1880.754 to 4074.881)63.175 (50.876 to 78.447)
SecondaryGMT of SARS-CoV-2 Neutralizing Antibody (Including True Virus-based SARS-CoV-2 Neutralizing Test)

At Day 7, Day 21 after first dose, at Day 7, Day 21 after second dose, and at Month 3, 6, and 12 after first dose.

Time frame:
Up to 12 months following first dose
Reported as:
Geometric mean · titer
GMT of SARS-CoV-2 Neutralizing Antibody (Including True Virus-based SARS-CoV-2 Neutralizing Test)
titerLow-dose 10 µg, 18-55 Years of AgeHigh-dose 30 µg, 18-55 Years of AgePlacebo, 18-55 Years of AgeLow-dose 10 µg, 65-85 Years of AgeHigh-dose 30 µg, 65-85 Years of AgePlacebo, 65-85 Years of Age
7 days after dose 15.000 (5.000 to 5.000)5.000 (5.000 to 5.000)5.000 (5.000 to 5.000)———
21 days after dose 118.877 (10.586 to 33.664)14.557 (9.712 to 21.817)5.000 (5.000 to 5.000)6.965 (5.037 to 9.633)10.946 (7.213 to 16.612)5.000 (5.000 to 5.000)
7 days after dose 256.569 (31.503 to 101.579)119.865 (81.547 to 176.187)5.000 (5.000 to 5.000)14.357 (8.689 to 23.721)49.394 (26.334 to 92.647)5.000 (5.000 to 5.000)
21 days after dose 2232.905 (151.299 to 358.525)253.984 (184.601 to 349.445)5.000 (5.000 to 5.000)80.000 (49.173 to 130.153)160.000 (96.736 to 264.637)5.000 (5.000 to 5.000)
Month 3 after dose 154.958 (38.115 to 79.245)87.241 (64.445 to 118.099)5.000 (5.000 to 5.000)———
Month 6 after dose 116.339 (11.274 to 23.679)27.479 (20.383 to 37.046)5.000 (5.000 to 5.000)10.000 (7.219 to 13.852)20.612 (13.303 to 31.937)5.000 (5.000 to 5.000)
Month 12 after dose 17.858 (6.027 to 10.244)11.892 (8.903 to 15.885)5.000 (5.000 to 5.000)6.040 (4.976 to 7.333)12.081 (8.154 to 17.899)5.000 (5.000 to 5.000)
SecondaryFold Increase in Antibody Anti-S1 IgG Antibody Titers, as Compared to Baseline

At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6, and 12 after dose 1.

Time frame:
Up to 12 months following the first dose
Reported as:
Geometric mean · fold rise
Fold Increase in Antibody Anti-S1 IgG Antibody Titers, as Compared to Baseline
fold riseLow-dose 10 µg, 18-55 Years of AgeHigh-dose 30 µg, 18-55 Years of AgePlacebo, 18-55 Years of AgeLow-dose 10 µg, 65-85 Years of AgeHigh-dose 30 µg, 65-85 Years of AgePlacebo, 65-85 Years of Age
7 days after dose 10.960 (0.899 to 1.025)0.998 (0.993 to 1.002)0.992 (0.976 to 1.008)———
21 days after dose 175.535 (45.607 to 125.103)76.351 (48.641 to 119.845)0.988 (0.962 to 1.013)16.501 (8.998 to 30.260)52.377 (30.969 to 88.586)0.997 (0.991 to 1.002)
7 days after dose 2478.186 (316.204 to 723.147)699.755 (473.456 to 1034.219)0.987 (0.961 to 1.014)101.189 (47.897 to 213.776)427.484 (281.104 to 650.090)1.003 (0.998 to 1.008)
21 days after dose 2843.129 (696.113 to 1021.194)838.640 (586.916 to 1198.328)0.939 (0.824 to 1.070)785.911 (631.437 to 978.175)805.108 (655.534 to 988.810)0.977 (0.896 to 1.065)
Month 3 after dose 1488.888 (359.289 to 665.234)532.172 (371.322 to 762.699)0.939 (0.824 to 1.070)———
Month 6 after dose 175.098 (50.105 to 112.558)95.924 (66.863 to 137.614)1.028 (0.939 to 1.126)42.685 (29.500 to 61.762)90.619 (64.457 to 127.399)0.966 (0.886 to 1.054)
Month 12 after dose 135.898 (23.326 to 55.246)47.053 (33.587 to 65.918)0.936 (0.817 to 1.073)21.169 (13.164 to 34.039)51.688 (34.959 to 76.423)0.842 (0.664 to 1.069)
SecondaryFold Increase in Antibody Anti-RBD IgG Antibody Titers, as Compared to Baseline

At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6, and 12 after dose 1.

Time frame:
Up to 12 months following first dose
Reported as:
Geometric mean · fold rise
Fold Increase in Antibody Anti-RBD IgG Antibody Titers, as Compared to Baseline
fold riseLow-dose 10 µg, 18-55 Years of AgeHigh-dose 30 µg, 18-55 Years of AgePlacebo, 18-55 Years of AgeLow-dose 10 µg, 65-85 Years of AgeHigh-dose 30 µg, 65-85 Years of AgePlacebo, 65-85 Years of Age
7 days after dose 11.000 (1.000 to 1.000)1.001 (0.998 to 1.005)0.985 (0.968 to 1.003)———
21 days after dose 1261.903 (167.900 to 408.537)246.976 (172.957 to 352.672)0.986 (0.964 to 1.009)51.597 (28.409 to 93.710)150.858 (74.500 to 305.479)1.001 (0.985 to 1.018)
7 days after dose 2766.291 (603.470 to 973.042)895.886 (778.927 to 1030.407)0.998 (0.973 to 1.023)182.382 (96.770 to 343.735)556.487 (351.897 to 880.024)1.020 (0.981 to 1.059)
21 days after dose 2994.206 (935.295 to 1056.827)969.249 (865.101 to 1085.934)1.054 (0.990 to 1.122)797.173 (645.312 to 984.773)741.532 (498.207 to 1103.699)0.884 (0.753 to 1.038)
Month 3 after dose 1804.724 (659.991 to 981.195)814.977 (706.611 to 939.963)1.051 (0.970 to 1.140)———
Month 6 after dose 1164.992 (123.722 to 220.029)181.895 (145.883 to 226.796)1.061 (0.889 to 1.267)69.813 (47.788 to 101.988)104.557 (65.750 to 166.268)0.764 (0.615 to 0.950)
Month 12 after dose 146.481 (33.557 to 64.383)53.098 (42.807 to 65.863)0.970 (0.893 to 1.053)25.871 (16.436 to 40.724)41.548 (25.869 to 66.729)0.835 (0.690 to 1.010)
SecondaryFold Increase in SARS-CoV-2 Neutralizing Antibody Titers (Virus Neutralizing Test), as Compared to Baseline.

At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6, and 12 after dose 1.

Time frame:
Up to 12 months following first dose
Reported as:
Geometric mean · fold rise
Fold Increase in SARS-CoV-2 Neutralizing Antibody Titers (Virus Neutralizing Test), as Compared to Baseline.
fold riseLow-dose 10 µg, 18-55 Years of AgeHigh-dose 30 µg, 18-55 Years of AgePlacebo, 18-55 Years of AgeLow-dose 10 µg, 65-85 Years of AgeHigh-dose 30 µg, 65-85 Years of AgePlacebo, 65-85 Years of Age
7 days after dose 11.000 (1.000 to 1.000)1.000 (1.000 to 1.000)1.000 (1.000 to 1.000)———
21 days after dose 13.775 (2.117 to 6.733)2.911 (1.942 to 4.363)1.000 (1.000 to 1.000)1.393 (1.007 to 1.927)2.189 (1.443 to 3.322)1.000 (1.000 to 1.000)
7 days after dose 211.314 (6.301 to 20.316)23.973 (16.309 to 35.237)1.000 (1.000 to 1.000)2.871 (1.738 to 4.744)9.879 (5.267 to 18.529)1.000 (1.000 to 1.000)
21 days after dose 246.581 (30.260 to 71.705)50.797 (36.920 to 69.889)1.000 (1.000 to 1.000)16.000 (9.835 to 26.031)32.000 (19.347 to 52.927)1.000 (1.000 to 1.000)
Month 3 after dose 110.992 (7.623 to 15.849)17.448 (12.889 to 23.620)1.000 (1.000 to 1.000)———
Month 6 after dose 13.268 (2.255 to 4.736)5.496 (4.077 to 7.409)1.000 (1.000 to 1.000)2.000 (1.444 to 2.770)4.122 (2.661 to 6.387)1.000 (1.000 to 1.000)
Month 12 after dose 11.572 (1.205 to 2.049)2.378 (1.781 to 3.177)1.000 (1.000 to 1.000)1.208 (0.995 to 1.467)2.416 (1.631 to 3.580)1.000 (1.000 to 1.000)
SecondarySeroconversion Rates (SCR) Defined as a Minimum of 4-fold Increase of Antibody Titers, as Compared to Baseline

At Day 7, Day 21 after dose 1, and at Day 7, Day 21 after dose 2.

Time frame:
Up to 21 days after dose 2
Reported as:
Count of participants · Participants
Seroconversion Rates (SCR) Defined as a Minimum of 4-fold Increase of Antibody Titers, as Compared to Baseline
ParticipantsLow-dose 10 µg, 18-55 Years of AgeHigh-dose 30 µg, 18-55 Years of AgePlacebo, 18-55 Years of AgeLow-dose 10 µg, 65-85 Years of AgeHigh-dose 30 µg, 65-85 Years of AgePlacebo, 65-85 Years of Age
SCR of SARS-CoV-2 neutralizing antibody - 7 days after dose 1000———
SCR of SARS-CoV-2 neutralizing antibody - 21 days after dose 112110380
SCR of SARS-CoV-2 neutralizing antibody - 7 days after dose 21823011180
SCR of SARS-CoV-2 neutralizing antibody - 21 days after dose 22424021220
SCR of anti-S1 IgG antibody - 7 days after dose 1000———
SCR of anti-S1 IgG antibody - 21 days after dose 12424021220
SCR of anti-S1 IgG antibody - 7 days after dose 22424022230
SCR of anti-S1 IgG antibody - 21 days after dose 22424023230
SCR of anti-RBD IgG antibody - 7 days after dose 1000———
SCR of anti-RBD IgG antibody - 21 days after dose 12424022220
SCR of anti-RBD IgG antibody - 7 days after dose 22424023230
SCR of anti-RBD IgG antibody - 21 days after dose 22424023230

Adverse events

Collected over From Day 1 (Dose 1) up to last visit (approximately 12 months after first dose). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low-dose 10 µg, 18-55 Years of Age0/24 (0%)0/24 (0%)22/24 (91.7%)
High-dose 30 µg, 18-55 Years of Age0/24 (0%)1/24 (4.2%)24/24 (100%)
Placebo, 18-55 Years of Age0/24 (0%)1/24 (4.2%)7/24 (29.2%)
Low-dose 10 µg, 65-85 Years of Age0/24 (0%)1/24 (4.2%)22/24 (91.7%)
High-dose 30 µg, 65-85 Years of Age0/24 (0%)0/24 (0%)24/24 (100%)
Placebo, 65-85 Years of Age0/24 (0%)0/24 (0%)9/24 (37.5%)
Most frequent serious events
Most frequent serious events
EventLow-dose 10 µg, 18-55 Years of AgeHigh-dose 30 µg, 18-55 Years of AgePlacebo, 18-55 Years of AgeLow-dose 10 µg, 65-85 Years of AgeHigh-dose 30 µg, 65-85 Years of AgePlacebo, 65-85 Years of Age
HyperthyroidismEndocrine disorders0/241/240/240/240/240/24
Thyroid massEndocrine disorders0/241/240/240/240/240/24
Thyroglossal cystCongenital, familial and genetic disorders0/240/241/240/240/240/24
Joint dislocationInjury, poisoning and procedural complications0/240/240/241/240/240/24
Humerus fractureInjury, poisoning and procedural complications0/240/240/241/240/240/24
Most frequent other events
Showing 10 of 55
Most frequent other events
EventLow-dose 10 µg, 18-55 Years of AgeHigh-dose 30 µg, 18-55 Years of AgePlacebo, 18-55 Years of AgeLow-dose 10 µg, 65-85 Years of AgeHigh-dose 30 µg, 65-85 Years of AgePlacebo, 65-85 Years of Age
Vaccination site painGeneral disorders21/2423/242/2416/2421/240/24
PyrexiaGeneral disorders14/2421/241/247/2419/241/24
HeadacheNervous system disorders11/2419/243/241/242/240/24
FatigueGeneral disorders13/2416/240/243/248/240/24
ArthralgiaMusculoskeletal and connective tissue disorders4/2410/241/240/241/241/24
MyalgiaMusculoskeletal and connective tissue disorders2/2410/240/240/241/241/24
MalaiseGeneral disorders8/249/240/242/244/241/24
Vaccination site erythemaGeneral disorders6/248/240/243/244/240/24
Vaccination site swellingGeneral disorders5/247/240/240/245/240/24
ChillsGeneral disorders4/247/240/241/244/240/24

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Low-dose 10 µg, 18-55 Years of AgeHigh-dose 30 µg, 18-55 Years of AgePlacebo, 18-55 Years of AgeLow-dose 10 µg, 65-85 Years of AgeHigh-dose 30 µg, 65-85 Years of AgePlacebo, 65-85 Years of AgeTotal
<=18 years0000000
Between 18 and 65 years24242400072
>=65 years00024242472
Age, Continuous
Age, Continuous(years)Low-dose 10 µg, 18-55 Years of AgeHigh-dose 30 µg, 18-55 Years of AgePlacebo, 18-55 Years of AgeLow-dose 10 µg, 65-85 Years of AgeHigh-dose 30 µg, 65-85 Years of AgePlacebo, 65-85 Years of AgeTotal
Group, 18-55 years of age38 ± 9.640 ± 9.042 ± 8.7———40 ± 9.2
Group, 65-85 years of age———71 ± 5.069 ± 3.071 ± 4.470 ± 4.2
Sex: Female, Male
Sex: Female, Male(Participants)Low-dose 10 µg, 18-55 Years of AgeHigh-dose 30 µg, 18-55 Years of AgePlacebo, 18-55 Years of AgeLow-dose 10 µg, 65-85 Years of AgeHigh-dose 30 µg, 65-85 Years of AgePlacebo, 65-85 Years of AgeTotal
Female12121212121272
Male12121212121272
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Low-dose 10 µg, 18-55 Years of AgeHigh-dose 30 µg, 18-55 Years of AgePlacebo, 18-55 Years of AgeLow-dose 10 µg, 65-85 Years of AgeHigh-dose 30 µg, 65-85 Years of AgePlacebo, 65-85 Years of AgeTotal
Asian242424242424144
Region of Enrollment
Region of Enrollment(participants)Low-dose 10 µg, 18-55 Years of AgeHigh-dose 30 µg, 18-55 Years of AgePlacebo, 18-55 Years of AgeLow-dose 10 µg, 65-85 Years of AgeHigh-dose 30 µg, 65-85 Years of AgePlacebo, 65-85 Years of AgeTotal
China242424242424144
Weight
Weight(kg)Low-dose 10 µg, 18-55 Years of AgeHigh-dose 30 µg, 18-55 Years of AgePlacebo, 18-55 Years of AgeLow-dose 10 µg, 65-85 Years of AgeHigh-dose 30 µg, 65-85 Years of AgePlacebo, 65-85 Years of AgeTotal
Group 18-55 years of age69.5 ± 12.0562.8 ± 10.7565.7 ± 13.26———66.0 ± 12.21
Group 65-85 years of age———61.8 ± 9.8363.8 ± 8.8159.0 ± 8.3661.5 ± 9.11
Body mass index (BMI)
Body mass index (BMI)(kg/m^2)Low-dose 10 µg, 18-55 Years of AgeHigh-dose 30 µg, 18-55 Years of AgePlacebo, 18-55 Years of AgeLow-dose 10 µg, 65-85 Years of AgeHigh-dose 30 µg, 65-85 Years of AgePlacebo, 65-85 Years of AgeTotal
Group 18-55 years of age24.7 ± 3.1823.0 ± 2.7124.3 ± 3.43———24.0 ± 3.16
Group 65-85 years of age———23.9 ± 2.9524.8 ± 2.8523.5 ± 2.4524.1 ± 2.77
08

Study locations

1 site
  • Jiangsu Provincial Center for Disease Control and Prevention
    Taizhou, Jiangsu 210009, China
09

References and documents

Publications

  • Li J, Hui AM, Zhang X, Ge L, Qiu Y, Tang R, Ye H, Wang X, Lin M, Zhu Z, Zheng J, Qiu J, Lagkadinou E, Shpyro S, Ozhelvaci O, Tureci O, Khondker Z, Yin W, Shishkova Y, Jia S, Pan H, Peng F, Ma Z, Wu Z, Guo X, Shi Y, Muik A, Sahin U, Zhu L, Zhu F. Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial. Adv Ther. 2022 Aug;39(8):3789-3798. doi: 10.1007/s12325-022-02206-1. Epub 2022 Jun 30. PubMed 35771353 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Sep 2020, 2 months.

Results were first posted in Sep 2023, 2 years 11 months after primary completion.

Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's 2 months is below that.

Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2020
First posted
Aug 21, 2020
StartActual
Jul 28, 2020
Primary completionActual
Sep 30, 2020
CompletionActual
Aug 10, 2021
Results first posted
Sep 18, 2023
Last update
Sep 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04523571
Lead sponsor
BioNTech SE
Responsible party
Sponsor
First posted
Aug 21, 2020
Start date
Jul 28, 2020
Primary completion
Sep 30, 2020
Completion
Aug 10, 2021
Results posted
Sep 18, 2023
Last update
Sep 18, 2023

Study contacts

BioNTech Responsible Person
study director · BioNTech SE

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BNT162 Vaccine

Start the discussion